Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. - Wikidata - wikimedia - TriplyDB

Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.

Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.

http://www.wikidata.org/entity/Q40209526

about

Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population.Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.

P2860

Q38794282-F593BB6F-98CC-4EBD-853E-9193A8D0956E Q47883565-E8177C1A-A91C-4F95-9113-F23F9FF9CB60

P2860

Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.

http://www.wikidata.org/entity/Q40209526

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Register-Based Evaluation of R ...... atment of Psoriasis in Sweden.

@en

type

label

Register-Based Evaluation of R ...... atment of Psoriasis in Sweden.

@en

prefLabel

Register-Based Evaluation of R ...... atment of Psoriasis in Sweden.

@en

P1433

Q40209526-EBF8E340-6401-404C-94D9-5E98C956E9E6

P1476

Q40209526-EE5FD80C-8CF2-4324-94C0-B8E3BAF0BB73

P2093

Q40209526-2203B1D6-1018-4022-8B46-369D31856E28

Q40209526-E3E6CA11-DB5A-47B9-8F4B-3244E05DC663

Q40209526-EB936604-7AA8-402D-88C1-C619816F607A

P2860

Q40209526-006832E9-68E2-4357-B2FD-5E00452AF2E0

Q40209526-023DBEE5-220A-48A2-8BAC-4FA92AF44F0F

Q40209526-0653C0FC-045F-4602-8CF2-9EAA426D2FD5

Q40209526-1372A0D7-AFA9-4A72-B243-2F6328480267

Q40209526-1854F65A-6F25-43F3-9409-6C3A10B78D7E

Q40209526-18FA944C-4C05-43A6-9CC5-A7EF3BA313A8

Q40209526-2A62355D-FE10-4A1D-9ACE-E6962528075F

Q40209526-3F41CFC8-23BE-4DB9-8B86-CD9E9C79F30E

Q40209526-40ACCAAA-EB5F-48CC-BEA0-179F2FB8DCE1

Q40209526-4807BAA7-371A-4826-A0A7-700FC2717F54

P2888

Q40209526-34E0F531-1B5C-412A-B4F0-09E59882B8B6

P304

Q40209526-8CB00805-A4F1-4996-8D78-7B25B5002AF9

P31

Q40209526-A87625AC-8FBE-4F9F-B86A-3FE3BAD5A03E

P356

Q40209526-33E5F688-C5A8-405F-9568-C772960B9D06

P433

Q40209526-C215639C-5901-4996-86A4-2055AE9C4E62

P478

Q40209526-E2D5E5A6-C281-4E93-985A-927CDF056996

P50

Q40209526-694FCBA4-2FA8-4ADE-8B0E-56E64D8B1643

P577

Q40209526-67FC7C57-637F-4BD8-9534-96E8961DC562

P5875

Q40209526-46F7B178-AF83-492D-82FF-92FC5E0ECD1D

P6179

Q40209526-9E3E133F-DA43-4EEF-ACF3-CC4B9D4EB81B

P698

Q40209526-82A399AD-7FA6-474F-A9B1-283945224BBA

P356

S40259-015-0151-4

P1433

P1476

Register-Based Evaluation of R ...... eatment of Psoriasis in Sweden

@en

P2093

Jenny M Norlin

http://www.w3.org/2001/XMLSchema#string

Katarina Steen Carlsson

http://www.w3.org/2001/XMLSchema#string

Ulf Persson

http://www.w3.org/2001/XMLSchema#string

P2860

Definition of treatment goals for moderate to severe psoriasis: a European consensus

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

EuroQol--a new facility for the measurement of health-related quality of life

Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study.

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and

Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database A

Ten years with biologics: to whom do data on effectiveness and safety apply?

P2888

s40259-015-0151-4

P304

389-398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40259-015-0151-4

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Marcus Schmitt-Egenolf

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287121358

http://www.w3.org/2001/XMLSchema#string

P6179

1018349012

http://www.w3.org/2001/XMLSchema#string

P698

26670179

http://www.w3.org/2001/XMLSchema#string